Table 2 Baseline characteristics of patients among different mean non-HDL-C groups
Parameter | Non-HDL-C <100 mg/dl (N = 299, 34%) | Non-HDL-C 100–130 mg/dl (N = 333, 38%) | Non-HDL-C >130 mg/dl (N = 236, 27%) | P-value |
|---|---|---|---|---|
Age (years) | 65.9 ± 11.0 | 62.5 ± 11.1 | 60.6 ± 11.0 | <0.001 |
Male | 66.2% | 60.1% | 59.3% | 0.173 |
Body mass index (kg/m2) | 22.5 ± 4.5 | 23.0 ± 5.5 | 23.4 ± 3.9 | 0.252 |
LVEF (%) | 49.9 ± 14.4 | 50.8 ± 13.0 | 50.0 ± 14.2 | 0.715 |
Creatinine (mg/dl) | 2.1 ± 8.7 | 1.7 ± 6.8 | 1.4 ± 2.2 | 0.528 |
Hemoglobin (g/dl) | 12.5 ± 2.5 | 12.5 ± 2.1 | 12.6 ± 2.0 | 0.681 |
Baseline LDL-C (mg/dl) | 101.1 ± 38.5 | 116.1 ± 39.6 | 131.7 ± 46.1 | <0.001 |
Baseline non-HDL-C (mg/dl) | 122.1 ± 38.7 | 142.1 ± 42.5 | 164.3 ± 51.4 | <0.001 |
Baseline HDL-C (mg/dl) | 39.7 ± 11.3 | 40.2 ± 11.0 | 39.8 ± 10.5 | 0.822 |
Smoking | 37.8% | 35.0% | 38.6% | 0.850 |
Hypertension | 57.9% | 59.2% | 53.8% | 0.477 |
Dyslipidemia | 25.8% | 34.2% | 38.6% | 0.0.05 |
Diabetes mellitus | 27.1% | 26.4% | 28.0% | 0.920 |
Chronic kidney disease | 9.0% | 5.4% | 7.2% | 0.210 |
History of CAD | 8.4% | 9.0% | 14.0% | 0.07 |
History of stroke | 5.0% | 3.9% | 4.7% | 0.788 |
STEMI | 79.3% | 79.9% | 72.5% | 0.181 |
Statin | 93.0% | 92.8% | 93.2% | 0.981 |
Ezetimibe | 3.3% | 2.4% | 6.8% | 0.024 |